Off-Label Promotion Prosecutors Watch Second-Generation Indications
Executive Summary
Federal prosecutors weighing action against off-label drug promotions will look carefully at the indications manufacturers seek for second-generation products as a marker for whether to pursue a case, Boston Assistant U.S. Attorney Michael Loucks told an American Conference Institute forum Oct. 21 in New York City
You may also be interested in...
Novartis Trileptal subpoena
Allegations of off label-promotion of Novartis' anti-epileptic Trileptal (oxcarbazepine) are under investigation by Philadelphia U.S. Attorney's Office, the company says July 14. The attorney's office issued a subpoena May 26 and is understood to have opened parallel civil and criminal investigations pursuant to privacy regulations under the Health Insurance Portability and Accountability Act. Boston Assistant U.S. Attorney Michael Loucks (now first assistant) has predicted that federal prosecutors are likely to bring lawsuits against drug companies that violate HIPAA's privacy provisions (1"The Pink Sheet" Nov. 3, 2003, p. 42)...
Novartis Trileptal subpoena
Allegations of off label-promotion of Novartis' anti-epileptic Trileptal (oxcarbazepine) are under investigation by Philadelphia U.S. Attorney's Office, the company says July 14. The attorney's office issued a subpoena May 26 and is understood to have opened parallel civil and criminal investigations pursuant to privacy regulations under the Health Insurance Portability and Accountability Act. Boston Assistant U.S. Attorney Michael Loucks (now first assistant) has predicted that federal prosecutors are likely to bring lawsuits against drug companies that violate HIPAA's privacy provisions (1"The Pink Sheet" Nov. 3, 2003, p. 42)...
Lilly Evaluating Audit Committee Responsibilities In Light Of New NYSE Rules
Lilly is evaluating the legal and regulatory oversight responsibilities of its audit committee in light of New York Stock Exchange Corporate Governance Rules